Cargando…

SUVmax and metabolic tumor volume: surrogate image biomarkers of KRAS mutation status in colorectal cancer

PURPOSE: The objective of this study was to explore the association between KRAS mutation status and PET/CT metabolic parameters in colorectal cancer (CRC) patients. MATERIALS AND METHODS: One hundred and sixty-four CRC patients were enrolled in this study and received PET/CT examination before oper...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lv, Ying, Wang, Xin, Liang, Lerong, Wang, Lei, Lu, Jie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6433102/ https://www.ncbi.nlm.nih.gov/pubmed/30962693 http://dx.doi.org/10.2147/OTT.S196725

Ejemplares similares

One-carbon metabolism biomarkers and genetic variants in relation to colorectal cancer risk by KRAS and BRAF mutation status
por: Myte, Robin, et al.
Publicado: (2018)

The Validity of Surrogate Endpoints in Sub Groups of Metastatic Colorectal Cancer Patients Defined by Treatment Class and KRAS Status
por: Poad, Heather, et al.
Publicado: (2022)

SUVmax—Δ makes the difference
por: Aigner, Clemens, et al.
Publicado: (2022)

The role of kras mutations and MSI status in diagnosis of colorectal cancer
por: Shemirani, Atena Irani, et al.
Publicado: (2011)

Different metastatic pattern according to the KRAS mutational status and site-specific discordance of KRAS status in patients with colorectal cancer
por: Kim, Mi-Jung, et al.
Publicado: (2012)

Analysis of KRAS Mutation Status Prediction Model for Colorectal Cancer Based on Medical Imaging
por: Ren, Zhen, et al.
Publicado: (2021)

Clinical-Pathological Correlation of KRAS Mutation Status in Metastatic Colorectal Adenocarcinoma
por: Ribeiro, Karen Bento, et al.
Publicado: (2013)

KRAS Mutation Status in Bulgarian Patients with Advanced and Metastatic Colorectal Cancer
por: Radanova, Maria, et al.
Publicado: (2023)

Are KRAS/BRAF Mutations Potent Prognostic and/or Predictive Biomarkers in Colorectal Cancers?
por: Yokota, Tomoya
Publicado: (2012)

Somatic mutation profiling and HER2 status in KRAS-positive Chinese colorectal cancer patients
por: Dong, Zhouhuan, et al.
Publicado: (2019)

Can the Ratio SUVmax of the Lesion/SUVmax of Mediastinal Tissues Guide the Choice of Surgical Access for the Resection of Thymic Epithelial Tumors?
por: Moraitis, Sotirios D., et al.
Publicado: (2022)

The preoperative SUVmax for (18)F-FDG uptake predicts survival in patients with colorectal cancer
por: Shi, Debing, et al.
Publicado: (2015)

SUVmax/THKmax as a Biomarker for Distinguishing Advanced Gastric Carcinoma from Primary Gastric Lymphoma
por: Fu, Liping, et al.
Publicado: (2012)

Retracted: Analysis of KRAS Mutation Status Prediction Model for Colorectal Cancer Based on Medical Imaging
por: Methods in Medicine, Computational and Mathematical
Publicado: (2023)

Construction of prediction model for KRAS mutation status of colorectal cancer based on CT radiomics
por: Cao, Yuntai, et al.
Publicado: (2023)

SUVmax/ADC Ratio as a Molecular Imaging Biomarker for Diagnosis of Biopsy-Naïve Primary Prostate Cancer
por: Chinnappan, Sheela, et al.
Publicado: (2021)

Impact of microsatellite status on chemotherapy for colorectal cancer patients with KRAS or BRAF mutation
por: Huang, Chi-Jung, et al.
Publicado: (2016)

The prognostic significance of KRAS and BRAF mutation status in Korean colorectal cancer patients
por: Won, Daeyoun David, et al.
Publicado: (2017)

Mutation Status and Immunohistochemical Correlation of KRAS, NRAS, and BRAF in 260 Chinese Colorectal and Gastric Cancers
por: Yang, Qiwei, et al.
Publicado: (2018)

Beyond KRAS mutation status: influence of KRAS copy number status and microRNAs on clinical outcome to cetuximab in metastatic colorectal cancer patients
por: Mekenkamp, Leonie JM, et al.
Publicado: (2012)

KRAS mutational analysis for colorectal cancer: Application: Pharmacogenomic
por: Wang, Grace, et al.
Publicado: (2010)

Preoperative metabolic tumor volume of intrahepatic cholangiocarcinoma measured by (18)F-FDG-PET is associated with the KRAS mutation status and prognosis
por: Ikeno, Yoshinobu, et al.
Publicado: (2018)

Distinct Clinicopathological Patterns of Mismatch Repair Status in Colorectal Cancer Stratified by KRAS Mutations
por: Li, Wenbin, et al.
Publicado: (2015)

Can Serum be Used for Analyzing the KRAS Mutation Status in Patients with Advanced Colorectal Cancer?
por: Kim, Seung Tae, et al.
Publicado: (2015)

Mutational status of plasma exosomal KRAS predicts outcome in patients with metastatic colorectal cancer
por: Lucchetti, Donatella, et al.
Publicado: (2021)

KRAS and BRAF mutations are prognostic biomarkers in patients undergoing lung metastasectomy of colorectal cancer
por: Renaud, S, et al.
Publicado: (2015)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

Impact of KRAS Mutations on Management of Colorectal Carcinoma
por: Sullivan, Kevin M., et al.
Publicado: (2011)

KRAS mutations in patients with colorectal cancer in Libya
por: Abudabous, Asma, et al.
Publicado: (2021)

The Therapeutic Landscape for KRAS-Mutated Colorectal Cancers
por: Tria, Simon Manuel, et al.
Publicado: (2023)

CT texture analysis of lung adenocarcinoma: can Radiomic features be surrogate biomarkers for EGFR mutation statuses
por: Mei, Dongdong, et al.
Publicado: (2018)

Pretreatment (18)F-FDG PET/CT Imaging Predicts the KRAS/NRAS/BRAF Gene Mutational Status in Colorectal Cancer
por: He, Peng, et al.
Publicado: (2021)

Transcriptional and metabolic rewiring of colorectal cancer cells expressing the oncogenic KRAS(G13D) mutation
por: Charitou, Theodosia, et al.
Publicado: (2019)

Prognostic value of KRAS mutation status in colorectal cancer patients: a population-based competing risk analysis
por: Dai, Dongjun, et al.
Publicado: (2020)

Heterogeneity of KRAS Mutation Status in Rectal Cancer
por: Jo, Peter, et al.
Publicado: (2016)

The correlation of SUVmax with pathological characteristics of primary tumor and the value of Tumor/ Lymph node SUVmax ratio for predicting metastasis to lymph nodes in resected NSCLC patients
por: Koksal, Deniz, et al.
Publicado: (2013)

KRAS-mutation status in relation to colorectal cancer survival: the joint impact of correlated tumour markers
por: Phipps, A I, et al.
Publicado: (2013)

KRAS Mutational Regression Is Associated With Oligo-Metastatic Status and Good Prognosis in Metastatic Colorectal Cancer
por: Ottaiano, Alessandro, et al.
Publicado: (2021)

KRAS, NRAS, BRAF signatures, and MMR status in colorectal cancer patients in North China
por: Lian, Shen-Yi, et al.
Publicado: (2023)

SUVmax of (18)F-FDG PET/CT in the differential diagnosis of benign and malignant thyroid nodules according to tumor volume
por: Kim, Tae Heon, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_rrqh461ffbcp0seffq96p367eb